Section

Medicine

Trials, therapies, and evidence that changes care.

Daily at 06:15 UTC

Edition No. 34
Updated UTC

Stronger verdicts first · Score orders stories within each verdict

Europe PMC

Verdict: Major

Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial

An unmet need persists for optimal myeloablative conditioning before allogeneic haematopoietic stem cell transplantation (HSCT) in adult KMT2A‑rearranged leukaemia.

By Hu, Fan, Dai +15The Lancet. Haematology

Score█████░░░░░5.4

Top stories

  1. 1. A multifaceted intervention to increase bystander CPR rates after out-of-hospital cardiac arrest in France: a stepped-wedge, cluster-randomised, controlled trial

    Bystander cardiopulmonary resuscitation (CPR) is a key determinant of survival after out-of-hospital cardiac arrest (OHCA), but rates remain suboptimal worldwide.

    Verdict: Major█████░░░░░5.4
  2. 2. Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial

    Trastuzumab rezetecan (SHR-A1811) has demonstrated encouraging antitumor activity in a global phase 1 trial involving heavily pretreated patients with erythroblastic oncogene B (ERBB2)-low metastatic breast…

    Verdict: Major█████░░░░░5.3

More top stories

No.03 to No.06

  1. Europe PMCby Hong, Zhou, Hou +43

    Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China

    Izalontamab brengitecan (iza-bren) is a first-in-class bispecific antibody-drug conjugate targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 ....

    No.03Verdict: MajorScore█████░░░░░5.3

Briefs

8 more from the desk